ClinicalTrials.gg
CompletedNCT05135390Updated Dec 31, 2024

A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients with Chronic Kidney Disease-Associated Pruritus

A Phase 3 interventional study of HSK21542 and Placebo in Pruritus and Hemodialysis Patients with Moderate-to-Severe Pruritus, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
545
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Pruritus with a site in China — 18 open to participants now, 20 under way, 4 of them phase 3. Pruritus · China.

Enrollment
Largest of 46
545 · median 92
Started
2022
with 2 others
Phase 3
11 of 48
4 open now
Registered
19th of 48
by date
Lead sponsor
3 of 48
Haisco Pharmaceutical Group Co., Ltd.

Among the 48 studies in Pruritus with a site in China, this one has the largest enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2022, is one of 11 in phase 3, and was the 19th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

18 of the 48 studies in Pruritus with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Pruritus with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, placebo-controlled study. About 544 maintenance hemodialysis patients with moderate or above chronic kidney disease-associated pruritus are planned to be enrolled. They will randomized into the treatment group (HSK21542, 0.3 μg/kg) and the control group (placebo) at a 1:1 ratio.

Read the detailed description

Double-blind Phase The Double-blind Phase of the study will consist of a 28-day Screening Visit, a 7-day Run-in Period, a 12 week Double-blind Treatment Period, and one week Follow-up Period. Informed consent will be obtained prior to performing any study-specific procedures. The Screening Visit will occur within 7 to 28 days prior to randomization to assess eligibility.

Open-label Extension Phase Patients who medication compliance ≥ 80% during the 12-week Double-blind Treatment Period and continue to meet other eligibility criteria will have the option to receive open label HSK21542 for an additional 40 weeks. The Open-label Extension Phase will be comprised of the Open-label Treatment Period and the Follow-up Period.

The last dose of open-label study drug will be administered at the last dialysis visit on Week 40, or Early Termination. A final safety Follow up Visit will be conducted 5-9 days after the End of Treatment/Early Termination Visit.

03

Conditions studied

  • Pruritus
  • Hemodialysis Patients with Moderate-to-Severe Pruritus

Browse trials for

Keywords

  • Hemodialysis Patients with Moderate-to-Severe Pruritus
  • HSK21542
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

The double-blind phase Inclusion Criteria:

  1. Subjects who are willing to sign an form, fully understand the objectives and significance of the trial, and are willing to comply with the trial protocol before any of the study-related procedures start;
  2. Aged ≥ 18 years old, male or female;
  3. Patients with end-stage renal disease, who have received regular hemodialysis (including hemodiafiltration) 3 times per week for at least 3 months prior to screening (the judgment of regular hemodialysis is subject to the joint medical comment of the investigator and the sponsor);
  4. Dry weight at screening: 40.0-135.0 kg (inclusive);
  5. On different days of hemodialysis within 6 months prior to administration, at least two occurrences of single-pool urea clearance index (sp Kt/V) ≥ 1.2 or at least two occurrences of urea reduction ratios (URR) ≥ 65%, or one occurrence of sp Kt/V ≥ 1.2 and one occurrence of URR ≥ 65%;
  6. Having completed at least 5 assessments of the Worst Itch Numeric Rating Scale from the lead-in period through D-1 and meeting the criteria of baseline itch intensity > 5 (defined as the average of all non-missing scores from the lead-in period to D-1; scores 0-10 indicates the range from no itch to the worst imaginable itch);
  7. Male subjects who agree to use condoms in sexual intercourse during the study and within 3 months after the last dose; female subjects who have been menopausal for at least one year, or who have been sterilized permanently (e.g., fallopian tube occlusion, hysterectomy, bilateral salpingectomy); or women of who agree to take effective measures during the study and within 3 months after the last dose, such as oral contraceptives, condoms, and contraceptive films.

The 0pen-label extension phase Inclusion Criteria:

  1. Dry weight ≥ 40 kg;
  2. Complete a double-blind study with medication adherence of ≥ 80%.

The double-blind phase Exclusion Criteria:

Exclusion criteria (those who meet any of the followings are ineligible):

  1. Expecting to undergo renal transplantation and/or parathyroidectomy during the study,or parathyroid hormone >800 pg/mL;
  2. Having a history of allergy to opioids, such as urticaria (Note: adverse effects related to opioid use, such as constipation and nausea, are not included as the exclusion criteria in this study);
  3. Having used opioids within 7 days before screening, or being unable to avoid the use of opioids other than the drug during the study;
  4. Having participated in any clinical trial of other drug or medical device within 1 month before screening (received study medication or treated by the medical device in the clinical trial);
  5. New or change of treatment received for hemoperfusion regimen within 3 months prior to screening or anticipating to adjust hemoperfusion regimen during the study;
  6. Upper extremity blood pressure in a supine position during screening: systolic blood pressure \< 90 mmHg, or diastolic blood pressure \< 60 mmHg, or systolic blood pressure > 180 mmHg, or diastolic blood pressure > 110 mmHg;
  7. (ALT) or AST (aspartate transaminase) > 2.5 × (ULN), or total > 2 × ULN at screening;
  8. Blood sodium > 155 mmol/L at screening;
  9. \< 80 g/L at screening;
  10. Positive for surface antigen (HBsAg), antibody (HCVAb), syphilis antibody, or (HIV) antibody at screening;
  11. Pruritus that may or must not be caused by ESRD or its complications (e.g., patients with pruritic dermatosis or cholestatic liver disease will be excluded);
  12. New or change of treatment received including antihistamines (oral, intravenous, or topical), systemic or topical (except for otic or ophthalmic preparations) , calcium regulated phosphatase inhibitors, gabapentin, pregabalin, and other combination drugs that are restricted in 5.5.1, or whose treatment regimen must be changed during the expected double-blind study periodwithin 7 days prior to screening or anticipating inevitable treatment regimen adjustment during the study;
  1. New or change of medications that may affect the judgment of antipruritic efficacy, including but not limited to antipsychotics, sedative-hypnotics, selective serotonin reuptake inhibitors (SSRIs), anxiolytics, or tricyclic antidepressants within 14 days prior to screening or anticipating inevitable treatment regimen adjustment during the study; 15. Females who are pregnant or breastfeeding; 16. Any physiological or psychological diseases or conditions that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's completion of the trial, as judged by the investigator, including but not limited to:
  1. Local pruritus limited to palms only;
  2. Pruritus during hemodialysis only;
  3. History of known or suspected abuse of or dependence on alcohol, narcotics or other drugs within 12 months before screening;
  4. Severe systolic or diastolic heart failure within 6 months prior to screening, e.g., Class IV congestive heart failure (see Appendix 7 for NYHA functional classification criteria);
  5. Severe mental illness or cognitive impairment (e.g., dementia);
  6. Any other relevant acute or chronic neurological or psychiatric condition within 3 months prior to screening that, at the discretion of the investigator, is not suitable for enrollment (e.g., encephalopathy, coma, delirium);
  7. Patients with , but excluding: curable cervical carcinoma in situ, skin basal cell or squamous cell carcinoma, or any other tumors that have been cured (no evidence of disease recurrence within 5 years).

The 0pen-label extension phase Exclusion Criteria:

  1. During the double-blind treatment period, an adverse event occurred that may affect the subject's continued receipt of the study drug;
  2. As determined by the investigator, there are any physical or psychological diseases or conditions that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's completion of the trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
545 participants (actual)

Study arms

  • Experimental
    HSK21542

    0.3 μg/kg

    Drug: HSK21542

  • Experimental
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • three times per week

  • DrugPlacebo

    three times per week

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with an improvement of ≥ 4 points from baseline in the weekly average of the daily Worst Itch Numeric Rating Scale (WI-NRS) after 12 weeks of treatment.

    In the NRS score, 0-10 represents different degrees of itching, the larger the number, the more severe the itching

    Time frame: week 12

Secondary outcomes

  1. Change from baseline in subjects' quality of life (evaluated using the Skindex-10 scale ) after 12 weeks of treatment.

    The Skindex-10 Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past week. The questions cover 3 domains: symptoms, emotions, and functioning domain. A lower total score represents better quality of life.

    Time frame: week 12

  2. Change from baseline in subjects' quality of life (evaluated using the 5-D itch scale) .

    The 5-D Itch Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past 2 weeks. The questions cover five dimensions of itch including the degree, duration of itch/day, direction (improvement/worsening), disability (impact on activities such as work), and body distribution of itch. A lower total score represents better quality of life.

    Time frame: Double-blind Phase:week 12,;Open-label Extension Phase: week 24, 40

  3. Proportion of subjects with an improvement of ≥ 3 points from baseline in the weekly average of the daily Worst Itch Numeric Rating Scale (WI-NRS) after 12 weeks of treatment.

    In the NRS score, 0-10 represents different degrees of itching, the larger the number, the more severe the itching

    Time frame: week 12

07

Study locations

2 sites
  • Zhong Da Hospital Southeast University
    Nanjing, Jiangsu, China
  • The First Affiliated Hospital, College of Medicine, Zhejiang University
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jul 2023, 13 months.

Of 42 industry-sponsored phase 3 interventional studies under Pruritus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 48 studies reached it within 19 months; a quarter within 12 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Nov 26, 2021
StartActual
Jun 17, 2022
Primary completionActual
Jul 27, 2023
CompletionActual
Jun 6, 2024
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05135390
Responsible party
Sponsor
First posted
Nov 26, 2021
Start date
Jun 17, 2022
Primary completion
Jul 27, 2023
Completion
Jun 6, 2024
Last update
Dec 31, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anrikefon

Start the discussion